The consensus among analysts is that TherapeuticsMD, Inc. (TXMD) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 2 out of 9 have rated it as a Hold, with 7 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.17.

TherapeuticsMD, Inc. (NASDAQ:TXMD) trade information

Despite being -1.67% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Jun 25 when the TXMD stock price touched $1.3 or saw a rise of 9.23%. Year-to-date, TherapeuticsMD, Inc. shares have moved -51.24%, while the 5-day performance has seen it change -0.84%. Over the past 30 days, the shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) have changed 4.42%. Short interest in the company has seen 82.99 Million shares shorted with days to cover at 15.26.

TherapeuticsMD, Inc. (TXMD) estimates and forecasts

8 analysts offering their estimates for the company have set an average revenue estimate of $10.2 Million for the current quarter. 8 have an estimated revenue figure of $16.67 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $5.12 Million and $23.72 Million respectively for this quarter and the next, and analysts expect sales will grow by 99.2% for the current quarter and -29.7% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -14.6% over the past 5 years. Earnings growth for 2020 is a modest -21.3% while over the next 5 years, the company’s earnings are expected to increase by 21.8%.

TherapeuticsMD, Inc. (NASDAQ:TXMD)’s Major holders

Insiders own 12.67% of the company shares, while shares held by institutions stand at 71.24% with a share float percentage of 81.57%. Investors are also buoyed by the number of investors in a company, with TherapeuticsMD, Inc. having a total of 216 institutions that hold shares in the company. The top two institutional holders are Price (T.Rowe) Associates Inc with over 19.36 Million shares worth more than $20.52 Million. As of March 30, 2020, Price (T.Rowe) Associates Inc held 7.13% of shares outstanding.

The other major institutional holder is JP Morgan Chase & Company, with the holding of over 19.28 Million shares as of March 30, 2020. The firm’s total holdings are worth over $20.44 Million and represent 7.1% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Price (T.Rowe) Small Cap Stock Fund and Fidelity Series Large Cap Stock Fund. As of December 30, 2019, the former fund manager holds about 3.53% shares in the company for having 9588712 shares of worth $23.2 Million while later fund manager owns 8.19 Million shares of worth $8.68 Million as of March 30, 2020, which makes it owner of about 3.01% of company’s outstanding stock.